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Abstract
Acquired resistance towards sorafenib treatment was found in HCC patients, which results in poor prognosis. To investigate
the enhanced metastatic potential of sorafenib resistance cells, sorafenib-resistant (SorR) cell lines were established by long-
term exposure of the HCC cells to the maximum tolerated dose of sorafenib. Cell proliferation assay and qPCR of ABC
transporter genes (ABCC1-3) were first performed to confirm the resistance of cells. Migration and invasion assays, and
immunoblotting analysis on the expression of epithelial to mesenchymal transition (EMT) regulatory proteins were
performed to study the metastatic potential of SorR cells. The expression of CD44 and CD133 were studied by flow
cytometry and the gene expressions of pluripotency factors were studied by qPCR to demonstrate the enrichment of cancer
stem cells (CSCs) in SorR cells. Control (CTL) and SorR cells were also injected orthotopically to the livers of NOD-SCID mice
to investigate the development of lung metastasis. Increased expressions of ABCC1-3 were found in SorR cells. Enhanced
migratory and invasive abilities of SorR cells were observed. The changes in expression of EMT regulatory proteins
demonstrated an activation of the EMT process in SorR cells. Enriched proportion of CD44+ and CD44+CD133+ cells were
also observed in SorR cells. All (8/8) mice injected with SorR cells demonstrated lung metastasis whereas only 1/8 mouse
injected with CTL cells showed lung metastasis. HCC cells with sorafenib resistance demonstrated a higher metastatic
potential, which may be due to the activated EMT process. Enriched CSCs were also demonstrated in the sorafenib resistant
cells. This study suggests that advanced HCC patients with acquired sorafenib resistance may have enhanced tumor growth
or distant metastasis, which raises the concern of long-term sorafenib treatment in advanced HCC patients who have
developed resistance of sorafenib.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth leading cancer in
men and the seventh leading cancer in women with a total of 0.7
million new cases worldwide [1]. Only a minority of HCC patients
are eligible to locoregional treatments including surgical resection
[2,3]. In addition, tumor response rate of HCC patients towards
systemic chemotherapy is low and chemoresistance can easily
develop [4–7]. HCC is still the second and the sixth leading cause
of cancer-related deaths in men and women, respectively, with
over half a million deaths worldwide [1] and the overall 5-year
survival rate of patients with advanced HCC is below 10% [8].
Therefore, it is of utmost importance to develop new medical
treatment especially for advanced HCC patients.
Sorafenib is an oral multikinase inhibitor, approved for the
treatment of advanced renal cell carcinoma and HCC by the U.S.
Food and Drug Administration and the European Medicine
Agency, targeting on Raf, epidermal growth factor receptor
(EGFR), vascular endothelial growth factor receptor (VEGFR),
platelet-derived growth factor receptor (PDGFR), FMS-like
tyrosine kinase-3 (Flt-3) and c-kit [9]. Sorafenib treatment was
found to be effective in inhibiting tumor growth and angiogenesis
in HCC by two large-scale, randomized, placebo-controlled
studies and the median overall survival rate is approximately 3
months longer in the sorafenib treatment group [10,11]. Recent
reports on patients with long-term treatment of sorafenib
demonstrated that only manageable adverse effects with mild-to-
moderate in severity were reported in patients with advanced non-
small-cell lung cancer [12], advanced renal cell carcinoma [13],
and advanced HCC [14].
Although sorafenib is a potent anti-cancer drug in treating
patients with advanced HCC, many patients still develop acquired
resistance to sorafenib [15]. A number of recent studies also
reported that many different pathways are involved in the
development of sorafenib resistance [16]. Chen et al. demonstrat-
ed that the activation of the PI3K/Akt signaling pathway mediates
the acquired sorafenib resistance in Huh7 cells [17]. In addition,
the expression level of EGFR was found to anticipate the efficacy
of sorafenib treatment [18] and blocking of EGFR and HER-3
phosphorylation sensitizes HCC cell response to sorafenib [19].
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Enrichment of cancer stem cells (CSCs) may also contribute to
sorafenib resistance. Label-retaining liver cancer cells, which
represent a novel subpopulation of CSCs, were found to be
resistant to sorafenib and these cells might contribute to disease
recurrence in HCC [20].
In view of the possibility of acquired sorafenib resistance with
long-term sorafenib treatment, the adverse effects brought by the
resistant cells were not known completely. In this study, three
HCC cell lines with sorafenib resistance were induced by long-
term cultured with sorafenib at the maximal tolerated dose.
Changes in cell morphology and the migratory and invasive
abilities of sorafenib resistant (SorR) cells were studied. We further
provide evidence to support that these changes were caused by the
activation of the EMT process. Enrichment of CD44+ and
CD44+CD133+ subpopulations of CSCs and enhanced expression
of pluripotency factors further suggested the possibility of tumor
recurrence or metastasis caused by SorR cells. Finally, animal
study was performed to demonstrate the increased incidence of
lung metastasis after inoculating SorR cells orthotopically to the
liver of mice. This study suggests that a higher metastatic potential
of HCC cells might be developed in HCC patients with acquired
sorafenib resistance, which brings out the concern of sorafenib
treatment in advanced HCC patients.
Materials and Methods
Drugs and Reagents
Sorafenib tosylate was provided by Bayer HealthCare Pharma-
ceuticals Inc. All reagents were purchased from Sigma-Aldrich (St.
Louis, MO, USA), unless specified below.
Cell Culture and Treatment
Human hepatoma PLC/PRF/5 (CRL-8024) (ATCC, Mana-
ssas, VA), HepG2 (HB-8065) (ATCC) and MHCC97L (Liver
Cancer Institute, Fudan University, Shanghai, China [21]) cells
were maintained in DMEM (Life Technologies, Carlsbad, CA)
containing 10% FBS (Life Technologies) and 1% Penicillin/
Streptomycin (Life Technologies), at 37uC humidified incubator
with 5% CO2 in the air. PLC/PRF/5 cells were stably transfected
with luciferase expressing construct for the ease of detection in the
in vivo study. For the development of sorafenib resistant cells
(SorR), cells were treated with 1 mM sorafenib and the concen-
tration of sorafenib was increased by 10% every two weeks until
the maximum tolerated doses have been reached and sorafenib
resistance have been developed. Equal volume of DMSO was
added to the control cells (CTL).
Cell Proliferation
The difference in sensitivity towards sorafenib treatment was
first examined by MTT assay as previously described [22]. Briefly,
CTL and SorR cells were plated in 96-well culture plates for 24
hours and media were replaced with culture medium with the
indicated concentrations (0–14 mM) of sorafenib. After 72 hours,
viability was assessed with the addition of MTT solution (1 mg/
ml) (Life Technologies). The percentage of surviving cells was
determined by dividing the average absorbance of sorafenib-
treated cells by the average absorbance of untreated cells from 3
replicate samples.
Actin Staining
CTL and SorR cells were plated in 8-well Millicell EZ slides
(Millipore, Billerica, MA), at 1000 cells per well. 24 hours after
attachment, cells were fixed with 4% paraformaldehyde at room
temperature for 5 min. Cells were then permeabilized with 0.2%
Triton X-100. Actin filaments were detected by incubating with
50 mg/ml TRITC conjugated phalloidin for 1 hour at room
temperature. After washing with PBS for several times, actin
filaments were visualized using a fluorescence microscope.
Migration and Invasion Transwell Assay
CTL and SorR cells were plated in top chambers of 24-well
transwell plates with 8 mm pores (Corning) and 24-well Bio-
CoatTM MatrigelTM Invasion chamber (BD Biosciences) at 16105
cells per well in DMEM with 1% FBS, for the study of migration
and invasion, respectively. 10% FBS was used as chemoattractant.
After 48 hours incubation, migrated or invaded cells were stained
with 0.2% crystal violet. The numbers of migrated and invaded
cells in four fields were counted under 1006magnification and the
average numbers of migrated and invaded cells were counted.
Immunoblotting
Total proteins were obtained by lysing CTL and SorR cells with
ice-cold RIPA buffer containing 150 mM NaCl, 1 mM EDTA,
1% NP-40, 0.25% sodium deoxycholate, 1 mM PMSF, and
protease inhibitor cocktail (Roche Diagnostics, Penzbery, Ger-
many) in 50 mM Tris-HCl buffer, pH 7.4. As for the nuclear
fraction, nuclear protein was obtained using the nuclear/cytosol
fractionation kit (Biovision, Milpitas, CA) according to the
manufacturer’s instruction. Total and nuclear protein were
subjected to immunoblotting as previously described [22]. Equal
amount of protein was loaded onto a 10% SDS-polyacrylamide
gel under reducing condition and transferred to PVDF membrane
(Amersham Bioscience, Piscataway, NJ). For the total protein
fraction, blots were probed with the following antibodies: E-
cadherin, Snail, N-cadherin (Novus Biologicals, Littleton, CO) and
Vimentin (Abcam) and expression of b-actin (Sigma-Aldrich) was
used as loading control. As for the nuclear fraction, blots were
probed with the following antibodies: b-catenin (BD Biosciences),
Smad2 (Cell signaling) and Smad3 (Cell signaling), and the
expression of nuclear matrix protein p84 (GeneTex, San Antonio,
TX) was used as loading control. After probing with horseradish
peroxidase-conjugated secondary antibodies, membranes were
developed with the Immobilon Western Chemiluminescent HRP
substrate system (Millipore).
Flow Cytometry on CD44 and CD133 Distribution
Harvested CTL and SorR cells were stained with CD44-FITC
(BD Pharmingen) and CD133-APC (Miltenyl Biotec, Auburn, CA)
antibodies in PBS with 1% BSA and 2 mM EDTA for 15 min at
room temperature in dark. Presence of CD44+ and CD133+ cells
were determined by Cytomics FC 500 flow cytometer (Beckman
Coulter, CA) and analyzed using FlowJo (version 8.7, Tree Star,
Inc.).
Quantitative Real Time PCR (qPCR)
Total RNA from CTL and SorR cells was extracted using
Trizol Reagent (Life Technologies) and purified using the
PureLink RNA Mini Kit (Life Technologies) according to the
manufacturer’s instructions. The concentration of RNA was
quantified by a NanoDrop spectrophotometer (Thermo Scientific,
Wilmington, DE). Complementary DNA (cDNA) was synthesized
from 1 mg RNA using superscript III reverse transcriptase (Life
Technologies). Primers (Life Technologies) used were listed in
Table 1. qPCR reactions were carried out using SYBR Green
PCR master mix (Life Technologies) according to the manufac-
turer’s instruction and run on a real-time PCR 7900 HT system
Sorafenib Resistance in Hepatocellular Carcinoma
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(Applied Biosystems, Foster City, CA). The expression level of b-
actin was used as internal control.
In vivo Study
Animal study was approved by the Committee on the Use of
Live Animals for Teaching and Research of the University of
Hong Kong (CULTR no. 2895-12). NOD/SCID mice were
maintained in laminar flow cabinets under pathogen-free condi-
tions. CTL and SorR cells, derived from PLC/PRF/5 cells, were
harvested from mid-log phase cultures and resuspended in a 50%
Matrigel (BD Biosciences) in culture medium. Cells (16107) were
injected under the capsule of the left liver lobe. Mice were
sacrificed at week 6. Under anesthesia, D-luciferin (Life Technol-
ogies) was injected i.p. and PLC/PRF/5 cells expressing luciferase
produced a bioluminance signal, which was detected by the IVIS
imaging system 100 (Xenogen, Alameda, CA). An elliptical region
of interest (ROI) was placed over the tumors, and the total signal
in the ROI (photons per second) was quantified using the Living
Image software (Xenogen). Liver and lung were dissected, fixed in
10% formalin, and paraffin-embedded for further analysis.
Immunohistochemistry (IHC) and Hematoxylin and Eosin
(H&E) Staining
The paraffin-embedded tissues were sectioned, deparaffinized
and rehydrated through a series of xylenes and ethanol. Antigen
retrieval was performed by boiling in sodium citrate buffer
(10 mmol/L sodium citrate, pH 6.0). Slides were then incubated
with anti-Ki-67 (Dako) or anti-CD44 (Dako) overnight at 4uC and
signal was detected by the LSAB+ System-HRP kits (Dako)
according to the manufacturer’s instruction. Sections were then
counterstained with hematoxylin and dehydrated through a series
of ethanol and xylenes.
For the staining of CD44 and Ki-67 of the primary tumors,
scoring of staining was performed by two independent investiga-
tors who were blinded to the study groups. The scoring was based
on the percentage and intensity of the positively stained cells under
high power (400X) microscopy. The staining of the protein of
interest was graded from 0–3 for intensity (0 = negative staining,
1 =weakly positive staining, 2 = moderately positive staining and
3= strongly positive staining) and percentage (0 = negative, 1 =
positive staining in ,30% of cells, 2 = 30–70% and 3= .70%),
respectively. The score of each section was the sum of both
parameters. Sections were also stained with Mayer’s hematoxylin
and eosin, and analyzed for metastasis.
Statistical Analysis
Data are presented as means 6 SD from three independent
experiments for the in vitro study and from n=8 for the in vivo
study. Data were statistically analyzed with one-way ANOVA, and
were considered statistically significant at p,0.05.
Results
Sorafenib-induced Resistance in HCC Cell Lines
SorR cells were first established by culturing PLC/PRF/5,
MHCC-97L and HepG2 cells in medium with increasing
concentration of sorafenib. The maximum tolerated dose of
sorafenib for PLC/PRF/5, MHCC-97L and HepG2 cells are
6 mM, 7 mM and 4 mM, respectively. MTT assays of different cell
lines demonstrated a significant difference of CTL and SorR cells
in response towards sorafenib treatment (Fig. 1A) and the IC50
value of sorafenib of different cell lines were shown in Table 2.
SorR cells demonstrated a higher IC50 value of sorafenib than the
CTL cells. In addition, SorR cells also showed a higher expression
of ABCC1, ABCC2 and ABCC3 than that of the CTL cells
(Fig. 1B), which further confirm the presence of drug resistance in
SorR cells.
Under a phase-contrast microscopy (4006), individual CTL
cells demonstrated circular shapes whereas individual SorR cells
with flattened and elongated shapes were observed (Fig. 1C).
Phalloidin staining of the actin filaments also demonstrated more
protrusions of the SorR cells than that of the CTL cells (Fig. 1D).
Enhanced Cellular Migration and Invasion, and EMT of
SorR Cells
We further compared the migratory and invasive ability of CTL
and SorR cells using the migration and invasion transwell assays.
When compared with the CTL cells, SorR cells demonstrated a 3-,
8-, and 2-fold higher in the numbers of migrated PLC/PRF/5,
MHCC-97L and HepG2 cells, respectively (Fig. 2A). Similarly,
SorR cells showed a 2-, 13-, and 9-fold higher in numbers of
invaded PLC/PRF/5, MHCC-97L and HepG2 cells, respectively
(Fig. 2B).
In order to explain the enhanced migratory and invasive ability
of the SorR cells, immunoblotting on the EMT regulatory
proteins, including E-cadherin, N-cadherin, Vimentin, and Snail,
and nuclear accumulation of b-catenin, Smad2 and Smad3 were
performed (Fig. 2C and 2D). In all cell lines, SorR cells
demonstrated a lower expression level of the epithelial marker
(E-Cadherin) with higher expression levels of mesenchymal
markers (N-Cadherin, Vimentin, and Snail) and a nuclear
accumulation of b-catenin, Smad2 and Smad3. These changes
in expression levels indicated an activation of the EMT process of
Table 1. Sequences of primer pairs.
Gene Sequence
ABC transporter proteins
ABCC1 F: 59-CCA TCC ACG ACC CTA ATC CC-39
R: 59-ACT TGT TCC GAC GTG TCC TC-39
ABCC2 F: 59-AGG TCA TCC TTT ACG GAG AAC A-39
R: 59-GTC CAG GAA TGA GGA ATT CCA AAA A-39
ABCC3 F: 59-GAC TCA GGC CAG TGT GTC TC-39
R: 59-GGT GCC ACT GTG TAT GGT GA-39
Pluripotent factors
Lin28 F: 59-GAA GGG TTC CGG AGC TTG AA-39
R: 59-ACA GTT GTA GCA CCT GTC TCC-39
Oct4 F: 59-GTG GAG GAA GCT GAC AAC AA-39
R: 59-GCC GGT TAC AGA ACC ACA CT-39
Nanog F: 59-CTG CAG AGA AGA GTG TCG CA-39
R: 59-ACC AGG TCT TCA CCT GTT TGT-39
Sox2 F: 59-GAC AGT TAC GCG CAC ATG AA-39
R: 59-TAG GTC TGC GAG CTG GTC AT-39
Msi1 F: 59-GGA GTT ATA CAG GCC TCG CC-39
R: 59-TGA GAG CCT GTC CCT CGA A-39
Hepatic growth factor and hepatic growth factor receptor
HGF F: 59-AGG ACT TCC ATT CAC TTG CAA GGC T-39
R: 59-ACT GTT CC TTG TAG CTG CGT CC-39
c-MET F: 59-GCC TGC AAT CTA CAA GGT TTT CCC A-39
R: 59-AGT CAA GGT GCA GCT CTC ATT TCC-39
doi:10.1371/journal.pone.0078675.t001
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SorR cells, which promote the enhanced migration and invasion
of SorR cells.
Enriched CSCs Subpopulations in SorR Cells
CD44 and CD133 are commonly used as cell surface markers
representing the cancer stem cells (CSCs) subpopulation in HCC
[23]. CSCs are resistant to conventional chemotherapy, and
therefore we further our study to investigate the enrichment of
CSCs in SorR cells using the cell surface marker of CD44 and
CD133 (Fig. 3A). SorR cells of all the three cell lines demonstrated
Figure 1. Establishment of SorR cells using HCC cell lines. PLC/PRF/5, MHCC97L and HepG2 cells were cultured at maximal tolerated dose of
sorafenib to obtain the CTL and SorR cells derived from each cell line. A) CTL and SorR cells were cultured at 0–14 mM sorafenib and MTT assay was
performed 72 hours after treatment. B) Total RNA from CTL and SorR cells were extracted to perform the qPCR analysis of ABCC1, ABCC2 and ABCC3.
C) Representing images of CTL and SorR cells under a phase-contrast microscopy (magnification: 400x). D) CTL and SorR cells were stained with
phalloidin (red) and counterstained by DAPI (blue). Representing images of CTL and SorR cells under a fluorescence microscopy (magnification: 400x).
Cellular protrusions were indicated by arrows. Data are presented as means6 SD from three independent experiments. *p,0.05 vs. CTL cells by one-
way ANOVA.
doi:10.1371/journal.pone.0078675.g001
Table 2. IC50 of CTL and SorR cells towards sorafenib
treatment.
PLC/PRF/5 MHCC-97L HepG2
CTL SorR CTL SorR CTL SorR
IC50 (mM) 8.04 .14 5.03 8.89 3.72 8.94
doi:10.1371/journal.pone.0078675.t002
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a significant enrichment of the CD44+ and CD44+CD133+
subpopulations but not the CD133+ subpopulations. In addition,
gene expression of the pluripotency factors was studied (Fig. 3B).
SorR cells of all the three cell lines demonstrated a significant
higher in expression of Lin28, Oct4 Nanog, Msi and SOX2 except
no difference was found in the expression of Lin28 and Msi1 in
HepG2 cells. These suggested that the enriched CSCs subpopu-
lation in SorR cells.
Higher Metastatic Potential of SorR Cells
For the in vivo study, orthotopic injection of the CTL and SorR
cells to the left liver lobe were done. Unexpectedly, tumor sizes
from CTL group were significantly larger than that from the SorR
group 6 weeks after injection (Fig. 4A and 4B). We further studied
on the metastatic potential of the cells and found that only 1 out of
8 mice demonstrated lung metastasis in CTL group whereas all (8
out of 8) mice demonstrated lung metastasis in SorR group
Figure 2. Enhanced cellular migration and invasion with activated EMT process of SorR cells. CTL and SorR cells derived from PLC/PRF/5,
MHCC97L and HepG2 cells were plated in top chambers to perform the migration and invasion assay. A) Representing images of the migrated cells
under a phase-contrast microscopy (magnification: 100x) were shown in the left panel and the number of migrated cells was counted and presented
in the right panel. B) Representing images of the invaded cells under a phase-contrast microscopy (magnification: 100x) were shown in the left panel
and the number of invaded cells was counted and presented in the right panel. Data are presented as means 6 SD from three independent
experiments. *p,0.05 vs. CTL cells by one-way ANOVA. C) Immunoblotting analysis demonstrated the change in total protein expression of E-
cadherin, N-cadherin, Vimentin and Snail. The expression level of b-actin was used as loading control. D) Immunoblotting analysis demonstrated the
change in protein expression of b-catenin, Smad2 and Smad3 from the nuclear fraction. The expression of nuclear matrix protein p84 was used as
loading control.
doi:10.1371/journal.pone.0078675.g002
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(Fig. 4C). IHC analysis on Ki-67 staining and H&E staining was
performed to confirm that the bioluminance signal was originated
from the metastatic lung (Fig. 4D). Positive signals of the Ki-67
staining represent the presence of human proliferating cells and
only lungs from the SorR group demonstrated a positive signal of
the Ki-67 staining. H&E staining also demonstrated a character-
Figure 3. Enriched CSCs subpopulation in SorR cells. A) Harvested CTL and SorR cells derived from PLC/PRF/5, MHCC97L and HepG2 cells were
stained with CD44 (FITC) and CD133 (APC) antibodies and 20000 cells were assessed by flow cytometry. The percentage of cells was indicated in each
quadrant. B) Total RNA from CTL and SorR cells were extracted to perform the qPCR analysis of Lin28, Oct4, Nanog, Msi1 and SOX2. Data are
presented as means 6 SD from three independent experiments. *p,0.05 vs. CTL cells by one-way ANOVA.
doi:10.1371/journal.pone.0078675.g003
Sorafenib Resistance in Hepatocellular Carcinoma
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istic spongy-like appearance of the lung section obtained from
CTL group whereas filling of the alveoli with neoplastic cells were
observed in the lung section obtained from SorR group. As the
expression of CD133 was undetected by IHC staining (data not
shown), only staining of CD44 and Ki-67 of the primary tumors
obtained from both CTL and SorR group were shown (Fig. 4E
and 4F). No positive signal was obtained for the staining of Ki-67
and CD44 from the adjacent liver tissues of both CTL and SorR
groups. When compared with the sections obtained from the
primary tumors of the CTL group, sections from the SorR group
demonstrated a stronger staining of CD44 and no significant
difference in the strength of signal of Ki-67 staining were obtained.
This in vivo study demonstrated a higher metastatic potential with
enriched CD44+ subpopulations in the SorR group.
Discussions
The complex biology of HCC makes it one of the most drug-
resistant tumors and intrinsic or acquired drug resistance can
easily develop. The development of sorafenib has been a great
hope to most advanced HCC patients due to the improved overall
survival benefit of sorafenib treatment. Unfortunately, clinical
evidence demonstrated the possibility of developing acquired
resistance to sorafenib in advanced HCC patients. In this study,
long-term exposure to sorafenib has successfully induced sorafenib
resistance in different HCC cell lines and both in vitro and in vivo
data demonstrated an increase in metastatic potential of the
resistant cells. This suggested that the high metastatic potential of
SorR cells is another potential risk of HCC patients who
developed sorafenib resistance.
EMT is a critical event in the development of the invasive and
metastatic potentials in cancer progression and EMT is initiated
by several inducers such as tumor growth factor- b (TGF-b) [24],
hepatocyte growth factor (HGF) [25], epidermal growth factor
(EGF) and Wnt, through the regulation of Wnt/b-catenin, TGF-
b/Smad, and Notch and Hedgehog (Hh) signaling pathways (as
reviewed in [26–29]). This complex signaling network starts with
the cleavage of E-cadherin, which causes adherens junction
breakdown and indirect increase in expression of transcription
factors, including zinc finger proteins of the snail/slug family and
b-catenin. The repression of E-cadherin by snail, or other
repressors leads indirectly to increase in expression of N-cadherin,
vimentin and other mesenchymal gene products. The cells then
acquired a more invasive and metastatic phenotype and numerous
studies have demonstrated the correlation of EMT activation with
poor prognosis including tumor relapse and metastasis [30–32].
The findings of this study is consistent with the results obtained in
a very recent study by Malenstein et al stating that long-term
exposure of HepG2 cells to sorafenib induces sorafenib resistance
with enhanced EMT and increased invasive ability [33]. In this
study, we further validate the activation of EMT process through
the in vivo study that demonstrated the success of lung metastasis.
Besides EMT, presence of CSCs also enhances the invasive and
metastatic potentials in cancer progression. CSCs are tumor-
initiating cells in the bulk of tumors that possess the ability to self-
renewal, divide and differentiate into multiple cell lineages. They
are multi-drug resistance and are able to initiate the formation of a
new tumor, leading to tumor recurrence and metastasis even after
removal of the primary tumor. Systemic chemotherapy is effective
in killing differentiated, fast-growing cancer cells. However, it
induces chemoresistance and it is well-known that chemotherapy
enriches CSCs population which highly increases the risk of
recurrence and metastasis. Similarly, in this study, sorafenib
resistance was also found to enrich CSCs population. Molecular
pathways including TGF-b, Wnt, Notch and Hh that modulate
EMT activation were also found in CSCs [34–36]. Therefore,
activation of the EMT process in SorR cells may also enrich the
CSCs subpopulation leading to the enhanced invasive and
metastatic potentials. Zhu et al suggested that CD133+CD44+
cells are subpopulation of cells processing CSCs properties in
HCC [23]. CD133+CD44+ cells demonstrated to process a higher
colony forming ability, a greater tumorigenicity in immunosup-
pressed mice, and are more resistance to doxorubicin treatment
when compared with the CD133+CD442 counterparts. In this
study, the CD44+ and CD133+CD44+ subpopulation of cells were
enriched in sorafenib resistant cells. In addition the expression of
some pluripotency factors were also enhanced in sorafenib
resistant cells and these further suggested the presence of stem-
like cells in the resistant cells. These findings further suggested the
potential recurrence and metastatic risk in HCC patients with
sorafenib resistance.
Some recent in vitro studies suggested that treatment with
sorafenib retained the levels of expression of ABCC1-3, which
were significant induced by treatment with gemcitabine and
doxorubicin, and hence sensitizes HCC cells towards doxorubicin
and gemcitabine treatments [37]. In another study, Nagai et al
suggested that treatment with sorafenib and U0125 (a MEK
inhibitor) of Huh7 and HepG2 markedly inhibited the HGF-
induced EMT by inhibiting EMT-like morphologic changes, snail
expression and E- to N-cadherin switching and thus completely
canceled the HGF-mediated cellular migration in HCC cells [38].
However, in this study SorR cells demonstrated a higher
expression of ABCC1-3 and an activation of the EMT process.
In addition, the RNA expression of HGF but not c-Met in SorR
cells is significantly higher than the CTL cells (Fig. S1), which may
further facilitate the EMT process. These suggested that inhibition
of the EMT process by sorafenib is effective in sorafenib sensitive
cells but sorafenib resistant cells retain the power of transition and
thus enhance the ability to migrate and invade.
In view of the ease of developing drug resistance towards mono-
therapy, an effective cancer therapy may require combination
chemotherapy. The combination chemotherapy can help to
reduce the chance of developing chemoresistance towards single
drug, target on different mechanisms during cancer development
to raise the chance of eliminating the cancer, and allow using
drugs at lower doses to reduce the chance of having toxic effects of
a single drug. Tai et al also demonstrated that STAT-3 is activated
in SorR cells and suggested that treatment with dovitinib, another
multikinase inhibitor, which effectively decreases phosphorylated
STAT3 by increasing SHP-1 activity, can overcome the sorafenib
resistance in HCC cells [39]. Another potential biomarker of the
sorafenib sensitivity is the activation of the PI3K/Akt pathway and
addition of an Akt inhibitor can restore the sorafenib sensitivity in
resistant cells. Therefore, by screening the expression of potential
markers, which determine the sorafenib sensitivity, one can predict
the tumor response towards sorafenib treatment and the addition
of a specific inhibitor may help to sensitize the tumors response
towards sorafenib. In addition, as both EMT and CSCs share
similar molecular pathways, molecular targeted drug targeting on
these specific pathways may help to completely eradicate the
cancer. Therefore, it is worthwhile to continue the study on
combination chemotherapy especially with molecular targeted
drugs, which helps to reduce the chance of developing drug
resistance to a mono-therapy, and enhance the anti-tumor efficacy
through different signaling pathways.
To conclude, long-term exposure of HCC cells with sorafenib
induced sorafenib resistance. The sorafenib resistant cells demon-
strated an activation of the EMT process with enhanced invasive
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Figure 4. Higher metastatic potential of SorR cells in an orthotopic model. CTL and SorR cells derived from PLC/PRF/5 cells were injected
under the capsule of the left liver lobe. A) Under anesthesia, bioluminance signal produced by the injected cells were measured to study the tumor
size at week 2, 4 and 6. B) Mice were sacrificed at week 6, bioluminance signal from primary tumor were detected to quantify the tumor size. C) Lung
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and metastatic potentials. The proportion of CSCs was also
enriched, which further suggested the potential risk of having
recurrence and developing distant metastasis in HCC. Currently,
sorafenib is the most potent drug prescribed to patients with
advanced HCC and it is a common practice for clinicians to
continue the sorafenib treatment even though the patients become
less responsive towards the treatment. However, this study
suggested that this might lead to the development of sorafenib
resistance, which increased the chance of developing distant
metastasis in HCC patients. A combination chemotherapy was
also suggested to prevent the development of sorafenib resistance
and enhance the therapeutic potential of the therapy in advanced
HCC patients.
Supporting Information
Figure S1 Gene expression of HGF and c-MET. Total
RNA from CTL and SorR cells derived from PLC/PRF/5,
MHCC97L and HepG2 cells were extracted to perform the qPCR
analysis of HGF and c-Met. Data are presented as means 6 SD
from three independent experiments. *p,0.05 vs. CTL cells by
one-way ANOVA.
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were isolated and bioluminance signal demonstrated the presence of injected cells which represents lung metastasis. D) Representing IHC staining of
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CTL and SorR group (magnification: 400x). F) The scoring of IHC staining of CD44 and Ki67 based on the percentage and intensity of the positively
stained cells under high power (400x) microscopy was performed. Data are presented as means 6 SD from 8 mice in each group. *p,0.05 vs. CTL
cells by one-way ANOVA.
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